{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:18:50Z","timestamp":1792019930800,"version":"4.4.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1K08HL166962"],"award-info":[{"award-number":["1K08HL166962"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11886-025-02255-2","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T08:30:20Z","timestamp":1750840220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lp(a): Global Public Health Concern: Emerging Knowledge and Therapeutic Approaches"],"prefix":"10.1007","volume":"27","author":[{"given":"Alexander C.","family":"Razavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"20","key":"2255_CR1","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.3390\/jcm11206040","volume":"11","author":"HS Bhatia","year":"2022","unstructured":"Bhatia HS, Wilkinson MJ. Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies. J Clin Med. 2022;11(20):6040.","journal-title":"J Clin Med"},{"issue":"12","key":"2255_CR2","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","volume":"77","author":"S Tsimikas","year":"2021","unstructured":"Tsimikas S, Moriarty PM, Stroes ES. Emerging RNA therapeutics to lower blood levels of Lp(a). J Am Coll Cardiol. 2021;77(12):1576\u201389.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2255_CR3","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844\u201353.","journal-title":"Eur Heart J"},{"issue":"18","key":"2255_CR4","doi-asserted-by":"publisher","first-page":"e031255","DOI":"10.1161\/JAHA.123.031255","volume":"12","author":"HS Bhatia","year":"2023","unstructured":"Bhatia HS, Hurst S, Desai P, Zhu W, Yeang C. Lipoprotein(a) testing trends in a large academic health system in the united States. J Am Heart Assoc. 2023;12(18):e031255.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"2255_CR5","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1093\/eurjpc\/zwae155","volume":"31","author":"CC Faaborg-Andersen","year":"2024","unstructured":"Faaborg-Andersen CC, Cho SMJ, Natarajan P, Honigberg MC. Trends and disparities in lipoprotein(a) testing in a large integrated US health system, 2000\u201323. Eur J Prev Cardiol. 2024;31(10):e79\u201382.","journal-title":"Eur J Prev Cardiol"},{"key":"2255_CR6","doi-asserted-by":"crossref","unstructured":"Dudum R, Huang Q, Yan X (Sherry), Fonseca MA, Jose P, Sarraju A Lipoprotein(a) Levels in Disaggregated Racial and Ethnic Subgroups Across Atherosclerotic Cardiovascular Disease Risk Levels, et al. editors. JACC: Advances. 2024;3(6).","DOI":"10.1016\/j.jacadv.2024.100940"},{"key":"2255_CR7","doi-asserted-by":"publisher","first-page":"100686","DOI":"10.1016\/j.ajpc.2024.100686","volume":"19","author":"Y Eidensohn","year":"2024","unstructured":"Eidensohn Y, Bhatla A, Ding J, Blumenthal RS, Martin SS, Marvel FA. Testing practices and clinical management of lipoprotein(a) levels: A 5-year retrospective analysis from the Johns Hopkins hospital. Am J Prev Cardiol. 2024;19:100686.","journal-title":"Am J Prev Cardiol"},{"issue":"5","key":"2255_CR8","doi-asserted-by":"publisher","first-page":"e720","DOI":"10.1016\/j.jacl.2024.07.003","volume":"18","author":"M Pavlyha","year":"2024","unstructured":"Pavlyha M, Li Y, Crook S, Anderson BR, Reyes-Soffer G. Race\/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice. J Clin Lipidol. 2024;18(5):e720\u20138.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2255_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1007\/s11606-024-09126-6","volume":"40","author":"S Brar","year":"2025","unstructured":"Brar S, Huang Q, Yan X, Dudum R, Jose P, Sarraju A, et al. Factors associated with Lipoprotein(a) testing among multiethnic individuals. J Gen Intern Med. 2025;40(4):756\u201363.","journal-title":"J Gen Intern Med"},{"key":"2255_CR10","doi-asserted-by":"crossref","unstructured":"Shah NP, Mulder H, Lydon E, Chiswell K, Hu X, Lampron Z et al. Lipoprotein (a) testing in patients with atherosclerotic cardiovascular disease in 5 large US health systems. J Am Heart Assoc. 2024;13(21):e035610.","DOI":"10.1161\/JAHA.124.035610"},{"issue":"1","key":"2255_CR11","first-page":"101441","volume":"4","author":"KF Faridi","year":"2025","unstructured":"Faridi KF, Wu Q, Kim C, Spatz ES, Desai NR, Krumholz HM, et al. Utilizing the electronic health record to evaluate Lipoprotein(a) testing within a large regional health system. JACC: Adv. 2025;4(1):101441.","journal-title":"JACC: Adv"},{"issue":"1","key":"2255_CR12","doi-asserted-by":"publisher","first-page":"e2453300","DOI":"10.1001\/jamanetworkopen.2024.53300","volume":"8","author":"T Chen","year":"2025","unstructured":"Chen T, Furst A, Din N, Gomez S, Maron DJ, Heidenreich P, et al. Lipoprotein a testing patterns in the veterans health administration. JAMA Netw Open. 2025;8(1):e2453300.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"2255_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1161\/CIRCULATIONAHA.124.070361","volume":"151","author":"A Bansal","year":"2025","unstructured":"Bansal A, Cho L. Prevalence of Lipoprotein(a) testing in a contemporary cohort. Circulation. 2025;151(9):649\u201351.","journal-title":"Circulation"},{"key":"2255_CR14","doi-asserted-by":"publisher","first-page":"100872","DOI":"10.1016\/j.ajpc.2024.100872","volume":"20","author":"SE Gomez","year":"2024","unstructured":"Gomez SE, Furst A, Chen T, Din N, Maron DJ, Heidenreich P, et al. Temporal trends in lipoprotein(a) testing among united States veterans from 2014 to 2023. Am J Prev Cardiol. 2024;20:100872.","journal-title":"Am J Prev Cardiol"},{"key":"2255_CR15","doi-asserted-by":"publisher","first-page":"100886","DOI":"10.1016\/j.ajpc.2024.100886","volume":"20","author":"M Manzato","year":"2024","unstructured":"Manzato M, Meeusen JW, Donato LJ, Jaffe AS, Vasile VC. Lipoprotein (a) testing patterns among subjects with a measured lipid panel: the Mayo clinic experience. Am J Prev Cardiol. 2024;20:100886.","journal-title":"Am J Prev Cardiol"},{"key":"2255_CR16","doi-asserted-by":"crossref","unstructured":"Razavi AC, Richardson LC, Coronado F, Vesper HW, Lyle A, Bhatia HS et al. Prevalence and correlates of Lipoprotein(a) testing in a diverse cohort of united States adults. JACC Adv. 2025;4(6_Part_1):101826.","DOI":"10.1016\/j.jacadv.2025.101826"},{"key":"2255_CR17","doi-asserted-by":"crossref","unstructured":"Loh WJ, Pang J, Simon O, Chan DC, Watts GF. Deficient perceptions and practices concerning elevated lipoprotein(a) among specialists in Singapore. Front Cardiovasc Med. 2025;12:1527351.","DOI":"10.3389\/fcvm.2025.1527351"},{"issue":"5","key":"2255_CR18","doi-asserted-by":"publisher","first-page":"e873","DOI":"10.1016\/j.jacl.2024.07.012","volume":"18","author":"J D\u2019Souza","year":"2024","unstructured":"D\u2019Souza J, Soffer DE, Bajaj A. Attitudes and barriers to lipoprotein(a) testing: A survey of providers at the university of Pennsylvania health system. J Clin Lipidol. 2024;18(5):e873\u20136.","journal-title":"J Clin Lipidol"},{"key":"2255_CR19","doi-asserted-by":"publisher","unstructured":"Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein (a) in clinical practice. J Clin Lipidol [Internet]. 2024;1\u201312. Available from: https:\/\/doi.org\/10.1016\/j.jacl.2024.03.001","DOI":"10.1016\/j.jacl.2024.03.001"},{"key":"2255_CR20","doi-asserted-by":"crossref","unstructured":"Aminorroaya A, Dhingra LS, Oikonomou EK, Khera R. Evaluation of a machine Learning-Guided strategy for elevated Lipoprotein(a) screening in health systems. Circ Genom Precis Med. 2025;18(1):e004632.","DOI":"10.1161\/CIRCGEN.124.004632"},{"key":"2255_CR21","doi-asserted-by":"publisher","first-page":"100895","DOI":"10.1016\/j.ajpc.2024.100895","volume":"21","author":"WE Eid","year":"2025","unstructured":"Eid WE, Sapp EH, Conroy C, Bessinger C, Moody CL, Yadav R, et al. Increasing provider awareness of Lp(a) testing for patients at risk for cardiovascular disease: A comparative study. Am J Prev Cardiol. 2025;21:100895.","journal-title":"Am J Prev Cardiol"},{"issue":"3","key":"2255_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/CIRCULATIONAHA.123.066398","volume":"149","author":"M Szarek","year":"2024","unstructured":"Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Diaz R, et al. Relating Lipoprotein(a) concentrations to cardiovascular event risk after acute coronary syndrome: A comparison of 3 tests. Circulation. 2024;149(3):192\u2013203.","journal-title":"Circulation"},{"key":"2255_CR23","doi-asserted-by":"crossref","unstructured":"Kronenberg F. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? Vol. 349, Atherosclerosis. 2022.","DOI":"10.1016\/j.atherosclerosis.2022.04.008"},{"issue":"5","key":"2255_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jacc.2024.10.081","volume":"85","author":"P Gaba","year":"2025","unstructured":"Gaba P, Rosenson RS, L\u00f3pez JAG, Watts GF, Leucker TM, Kuder JF, et al. Intraindividual variability in serial Lipoprotein(a) concentrations among Placebo-Treated patients in the OCEAN(a)-DOSE trial. J Am Coll Cardiol. 2025;85(5):550\u20133.","journal-title":"J Am Coll Cardiol"},{"key":"2255_CR25","doi-asserted-by":"crossref","unstructured":"Awad K, Mahmoud AK, Abbas MT, Alsidawi S, Ayoub C, Arsanjani R et al. Intra-individual variability in lipoprotein(a) levels: findings from a large academic health system population. Eur J Prev Cardiol. 2024;zwae341.","DOI":"10.1093\/eurjpc\/zwae341"},{"issue":"7","key":"2255_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","volume":"79","author":"M Trinder","year":"2022","unstructured":"Trinder M, Paruchuri K, Haidermota S, Bernardo R, Zekavat SM, Gilliland T, et al. Repeat measures of Lipoprotein(a) molar concentration and cardiovascular risk. J Am Coll Cardiol. 2022;79(7):617\u201328.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2255_CR27","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/eurheartj\/ehae652","volume":"46","author":"J Ghouse","year":"2025","unstructured":"Ghouse J, Ahlberg G, Albertsen Rand S, Salling Olesen M, Vilhjalmsson B, Stender S, et al. Within-person stability of lipoprotein(a) concentration. Eur Heart J. 2025;46(12):1159\u201361.","journal-title":"Eur Heart J"},{"issue":"1","key":"2255_CR28","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48\u201360.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"2255_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","volume":"151","author":"HS Bhatia","year":"2025","unstructured":"Bhatia HS, Wandel S, Willeit P, Lesogor A, Bailey K, Ridker PM, et al. Independence of lipoprotein(a) and Low-Density lipoprotein Cholesterol\u2013Mediated cardiovascular risk: A Participant-Level Meta-Analysis. Circulation. 2025;151(4):312\u201321.","journal-title":"Circulation"},{"issue":"3","key":"2255_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","volume":"83","author":"E Bj\u00f6rnson","year":"2024","unstructured":"Bj\u00f6rnson E, Adiels M, Taskinen MR, Burgess S, Chapman MJ, Packard CJ, et al. Lipoprotein(a) is markedly more atherogenic than LDL. J Am Coll Cardiol. 2024;83(3):385\u201395.","journal-title":"J Am Coll Cardiol"},{"key":"2255_CR31","doi-asserted-by":"crossref","unstructured":"Zhang W, Speiser JL, Ye F, Tsai MY, Cainzos-Achirica M, Nasir K et al. High-Sensitivity C-Reactive protein modifies the cardiovascular risk of Lipoprotein(a): Multi-Ethnic study of atherosclerosis. J Am Coll Cardiol. 2021;78(11):1083\u201394.","DOI":"10.1016\/j.jacc.2021.07.016"},{"issue":"4","key":"2255_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jamacardio.2023.5605","volume":"9","author":"AM Small","year":"2024","unstructured":"Small AM, Pournamdari A, Melloni GEM, Scirica BM, Bhatt DL, Raz I, et al. Lipoprotein(a), C-Reactive protein, and cardiovascular risk in primary and secondary prevention populations. JAMA Cardiol. 2024;9(4):385.","journal-title":"JAMA Cardiol"},{"issue":"12","key":"2255_CR33","first-page":"101409","volume":"3","author":"PL Alebna","year":"2024","unstructured":"Alebna PL, Han CY, Ambrosio M, Kong G, Cyrus JW, Harley K, et al. Association of Lipoprotein(a) with major adverse cardiovascular events across hs-CRP. JACC: Adv. 2024;3(12):101409.","journal-title":"JACC: Adv"},{"key":"2255_CR34","doi-asserted-by":"crossref","unstructured":"Thomas PE, Vedel-Krogh S, Afzal S, Nordestgaard BG, Kamstrup PR. Lipoprotein(a)-associated risk of atherosclerotic cardiovascular disease is independent of C-reactive protein. Eur J Prev Cardiol. 2024;zwae364.","DOI":"10.1093\/eurjpc\/zwae364"},{"key":"2255_CR35","doi-asserted-by":"crossref","unstructured":"Girard A, Gaillard E, Puri R, Capoulade R, Chan KL, Paulin A et al. Impact of C-reactive protein levels on lipoprotein(a)-associated aortic stenosis incidence and progression. Eur Heart J Open. 2023;3(2):oead032.","DOI":"10.1093\/ehjopen\/oead032"},{"key":"2255_CR36","doi-asserted-by":"crossref","unstructured":"Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE, Inflammation. Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women. New England Journal of Medicine. 2024.","DOI":"10.1056\/NEJMoa2405182"},{"key":"2255_CR37","doi-asserted-by":"publisher","first-page":"100903","DOI":"10.1016\/j.ajpc.2024.100903","volume":"21","author":"SO Nomura","year":"2025","unstructured":"Nomura SO, Bhatia HS, Garg PK, Karger AB, Guan W, Cao J, et al. Lipoprotein(a), high-sensitivity c-reactive protein, homocysteine and cardiovascular disease in the Multi-Ethnic study of atherosclerosis. Am J Prev Cardiol. 2025;21:100903.","journal-title":"Am J Prev Cardiol"},{"issue":"2","key":"2255_CR38","first-page":"100800","volume":"3","author":"MN Trinh","year":"2024","unstructured":"Trinh MN, Pournamdari A, Small AM, Peloso GM, Patel AP, Natarajan P. Lipoprotein(a) concentrations are independent of polygenic score for coronary artery disease. JACC: Adv. 2024;3(2):100800.","journal-title":"JACC: Adv"},{"issue":"16","key":"2255_CR39","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jacc.2024.02.031","volume":"83","author":"ND Wong","year":"2024","unstructured":"Wong ND, Fan W, Hu X, Ballantyne C, Hoodgeveen RC, Tsai MY, et al. Lipoprotein(a) and Long-Term cardiovascular risk in a Multi-Ethnic pooled prospective cohort. J Am Coll Cardiol. 2024;83(16):1511\u201325.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2255_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12933-024-02348-2","volume":"23","author":"A Shiyovich","year":"2024","unstructured":"Shiyovich A, Berman AN, Besser SA, Biery DW, Cardoso R, Divakaran S, et al. Lipoprotein(a) as a cardiovascular risk factor among patients with and without diabetes mellitus: the mass general Brigham Lp(a) registry. Cardiovasc Diabetol. 2024;23(1):257.","journal-title":"Cardiovasc Diabetol"},{"key":"2255_CR41","doi-asserted-by":"crossref","unstructured":"Kim K, Kim M, Han J, Jung H, Kim AR, Jun TJ et al. Impact of diabetes on risk of major adverse cardiovascular events associated with lipoprotein(a) levels in patients with established atherosclerotic cardiovascular disease. Eur J Prev Cardiol. 2025;zwaf036.","DOI":"10.1093\/eurjpc\/zwaf036"},{"key":"2255_CR42","doi-asserted-by":"crossref","unstructured":"Razavi AC, Blaha MJ, Bhatia HS. Inconsistent association between Lipoprotein(a) and coronary artery calcium. Eur J Prev Cardiol. 2025;zwaf196.","DOI":"10.1093\/eurjpc\/zwaf196"},{"issue":"9","key":"2255_CR43","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1001\/jamacardio.2024.1874","volume":"9","author":"NS Nurmohamed","year":"2024","unstructured":"Nurmohamed NS, Gaillard EL, Malkasian S, de Groot RJ, Ibrahim S, Bom MJ, et al. Lipoprotein(a) and Long-Term plaque progression, Low-Density plaque, and pericoronary inflammation. JAMA Cardiol. 2024;9(9):826.","journal-title":"JAMA Cardiol"},{"key":"2255_CR44","doi-asserted-by":"crossref","unstructured":"Mszar R, Cainzos-Achirica M, Valero-Elizondo J, Lahan S, Al-Kindi SG, Quispe R et al. Lipoprotein(a) and coronary plaque in asymptomatic individuals: the Miami heart study at baptist health South Florida. Circ Cardiovasc Imaging. 2024;17(7):e016152.","DOI":"10.1161\/CIRCIMAGING.123.016152"},{"key":"2255_CR45","doi-asserted-by":"publisher","unstructured":"Kim BJ, Kang J. Association of lipoprotein(a) and coronary artery calcium with atherosclerotic cardiovascular disease. J Clin Lipidol. 2025. https:\/\/doi.org\/10.1016\/j.jacl.2025.02.007","DOI":"10.1016\/j.jacl.2025.02.007"},{"issue":"4","key":"2255_CR46","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jacl.2023.06.002","volume":"17","author":"CL Jackson","year":"2023","unstructured":"Jackson CL, Garg PK, Guan W, Tsai MY, Criqui MH, Tsimikas S, et al. Lipoprotein(a) and coronary artery calcium in comparison with other lipid biomarkers: the multi-ethnic study of atherosclerosis. J Clin Lipidol. 2023;17(4):538\u201348.","journal-title":"J Clin Lipidol"},{"issue":"10","key":"2255_CR47","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jcmg.2024.05.023","volume":"17","author":"ND Wong","year":"2024","unstructured":"Wong ND, Fan W, Hu X, Ballantyne C, Hoogeveen R, Tsai MY, et al. Lipoprotein(a) and progression of coronary artery calcification in a pooled U.S. Cohort. JACC Cardiovasc Imaging. 2024;17(10):1265\u20137.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2255_CR48","doi-asserted-by":"crossref","unstructured":"Mehta A, Vasquez N, Ayers CR, Patel J, Hooda A, Khera A et al. Independent association of Lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol. 2022;79(8):757\u201368.","DOI":"10.1016\/j.jacc.2021.11.058"},{"issue":"7","key":"2255_CR49","first-page":"101049","volume":"3","author":"KF Faridi","year":"2024","unstructured":"Faridi KF, Lahan S, Budoff MJ, Cury RC, Feldman T, Pan AP, et al. Serum lipoproteins are associated with coronary atherosclerosis in asymptomatic U.S. Adults without traditional risk factors. JACC: Adv. 2024;3(7):101049.","journal-title":"JACC: Adv"},{"key":"2255_CR50","doi-asserted-by":"crossref","unstructured":"Shiyovich A, Berman AN, Besser SA, Biery DW, Kaur G, Divakaran S et al. Association of lipoprotein (a) and standard modifiable cardiovascular risk factors with incident myocardial infarction: the mass general Brigham Lp(a) registry. J Am Heart Assoc. 2024;13(10):e034493.","DOI":"10.1161\/JAHA.123.034493"},{"key":"2255_CR51","doi-asserted-by":"crossref","unstructured":"Razavi AC, Reyes MP, Wilkins JT, Szklo MS, Tsai MY, Whelton SP et al. Traditional risk factors, optimal cardiovascular health, and elevated lipoprotein(a). Eur J Prev Cardiol. 2024;zwae382.","DOI":"10.1093\/eurjpc\/zwae382"},{"issue":"15","key":"2255_CR52","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1093\/eurjpc\/zwae212","volume":"31","author":"AK Mahmoud","year":"2024","unstructured":"Mahmoud AK, Farina JM, Awad K, Ali NB, Pereyra M, Scalia IG, et al. Lipoprotein(a) and long-term in-stent restenosis after percutaneous coronary intervention. Eur J Prev Cardiol. 2024;31(15):1878\u201387.","journal-title":"Eur J Prev Cardiol"},{"issue":"25","key":"2255_CR53","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.jacc.2024.08.070","volume":"84","author":"HS Bhatia","year":"2024","unstructured":"Bhatia HS, Dweck MR, Craig N, Capoulade R, Pibarot P, Trainor PJ, et al. Oxidized phospholipids and calcific aortic valvular disease. J Am Coll Cardiol. 2024;84(25):2430\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"2255_CR54","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","volume":"82","author":"PE Thomas","year":"2023","unstructured":"Thomas PE, Vedel-Krogh S, Nielsen SF, Nordestgaard BG, Kamstrup PR. Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events. J Am Coll Cardiol. 2023;82(24):2265\u201376.","journal-title":"J Am Coll Cardiol"},{"key":"2255_CR55","doi-asserted-by":"crossref","unstructured":"Awad K, Kamel M, Mahmoud AK, Farina JM, Badr A, Pereyra Pietri M et al. Elevated lipoprotein(a) levels linked to new-onset atrial fibrillation: insights from a retrospective cohort study. Eur J Prev Cardiol. 2025;zwaf063.","DOI":"10.1093\/eurjpc\/zwaf063"},{"issue":"24","key":"2255_CR56","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1016\/j.jacc.2024.08.059","volume":"84","author":"S Bay Simony","year":"2024","unstructured":"Bay Simony S, R\u00f8rb\u00e6k Kamstrup P, B\u00f8dtker Mortensen M, Afzal S, Gr\u00f8nne Nordestgaard B, Langsted A. High Lipoprotein(a) as a cause of kidney disease. J Am Coll Cardiol. 2024;84(24):2407\u201310.","journal-title":"J Am Coll Cardiol"},{"key":"2255_CR57","doi-asserted-by":"crossref","unstructured":"Januzzi JL, van Kimmenade RRJ, Liu Y, Hu X, Browne A, Plutzky J et al. Lipoprotein(a), oxidized phospholipids, and progression to symptomatic heart failure: the CASABLANCA study. J Am Heart Assoc. 2024;13(12):e034774.","DOI":"10.1161\/JAHA.124.034774"},{"key":"2255_CR58","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1161\/CIRCULATIONAHA.109.192703","volume":"121","author":"DM Lloyd-Jones","year":"2010","unstructured":"Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. Defining and setting National goals for cardiovascular health promotion and disease reduction: the American heart association\u2019s strategic impact goal through 2020 and beyond. Circulation. 2010;121:586\u2013613.","journal-title":"Circulation"},{"issue":"24","key":"2255_CR59","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275\u201384.","journal-title":"Eur Heart J"},{"issue":"6","key":"2255_CR60","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","volume":"37","author":"MJ Lipinski","year":"2016","unstructured":"Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC, et al. The impact of proprotein convertase subtilisin-kexin type 9 Serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J. 2016;37(6):536\u201345.","journal-title":"Eur Heart J"},{"key":"2255_CR61","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","DOI":"10.1056\/NEJMoa1801174"},{"issue":"12","key":"2255_CR62","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk insights from the FOURIER trial. Circulation. 2019;139(12):1483\u201392.","journal-title":"Circulation"},{"key":"2255_CR63","doi-asserted-by":"crossref","unstructured":"Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM et al. Effect of Alirocumab on Lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133\u201344.","DOI":"10.1016\/j.jacc.2019.10.057"},{"issue":"2","key":"2255_CR64","first-page":"101549","volume":"4","author":"FB Rivera","year":"2025","unstructured":"Rivera FB, Cha SW, Linnaeus Louisse C, Carado GP, Magalong JV, Tang VA, et al. Impact of proprotein convertase subtilisin\/kexin type 9 inhibitors on Lipoprotein(a). JACC: Adv. 2025;4(2):101549.","journal-title":"JACC: Adv"},{"issue":"5","key":"2255_CR65","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","volume":"78","author":"GG Schwartz","year":"2021","unstructured":"Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, et al. Lipoprotein(a) and benefit of PCSK9 Inhibition in patients with nominally controlled LDL cholesterol. J Am Coll Cardiol. 2021;78(5):421\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2255_CR66","doi-asserted-by":"publisher","first-page":"e016683","DOI":"10.1161\/CIRCIMAGING.124.016683","volume":"17","author":"KC Koskinas","year":"2024","unstructured":"Koskinas KC, H\u00e4ner J, Ueki Y, Otsuka T, Lonborg J, Shibutani H, et al. Association of Lipoprotein(a) with changes in coronary atherosclerosis in patients treated with Alirocumab. Circ Cardiovasc Imaging. 2024;17(11):e016683.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"2255_CR67","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/dc24-2110","volume":"48","author":"GG Schwartz","year":"2025","unstructured":"Schwartz GG, Szarek M, Jukema JW, Cobbaert CM, Reijnders E, Bittner VA, et al. Risk of incident diabetes related to Lipoprotein(a), LDL cholesterol, and their changes with alirocumab: post hoc analyses of the ODYSSEY OUTCOMES randomized trial. Diabetes Care. 2025;48(4):596\u2013604.","journal-title":"Diabetes Care"},{"key":"2255_CR68","unstructured":"Kaneka Medical America LLC. 2025 LIPOSORBER LA-15 Instructions for use in Familial Hypercholesterolemia (FH), Section IV."},{"key":"2255_CR69","doi-asserted-by":"crossref","unstructured":"Gianos E, Duell PB, Toth PP, Moriarty PM, Thompson GR, Brinton EA et al. Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: A scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2024;44(12):e304\u201321.","DOI":"10.1161\/ATV.0000000000000177"},{"key":"2255_CR70","doi-asserted-by":"crossref","unstructured":"Bhatia HS, Becker RC, Leibundgut G, Patel M, Lacaze P, Tonkin A et al. Lipoprotein(a), platelet function and cardiovascular disease. Nat Rev Cardiol. 2024;21:299\u2013311.","DOI":"10.1038\/s41569-023-00947-2"},{"issue":"1","key":"2255_CR71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11883-025-01296-w","volume":"27","author":"AC Razavi","year":"2025","unstructured":"Razavi AC, Bhatia HS. Role of aspirin in reducing risk for atherosclerotic cardiovascular disease in individuals with elevated Lipoprotein(a). Curr Atheroscler Rep. 2025;27(1):49.","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"2255_CR72","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","volume":"203","author":"DI Chasman","year":"2009","unstructured":"Chasman DI, Shiffman D, Zee RYL, Louie JZ, Luke MM, Rowland CM, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009;203(2):371\u20136.","journal-title":"Atherosclerosis"},{"issue":"14","key":"2255_CR73","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","volume":"80","author":"P Lacaze","year":"2022","unstructured":"Lacaze P, Bakshi A, Riaz M, Polekhina G, Owen A, Bhatia HS, et al. Aspirin for primary prevention of cardiovascular events in relation to Lipoprotein(a) genotypes. J Am Coll Cardiol. 2022;80(14):1287\u201398.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2255_CR74","doi-asserted-by":"publisher","first-page":"e033562","DOI":"10.1161\/JAHA.123.033562","volume":"13","author":"HS Bhatia","year":"2024","unstructured":"Bhatia HS, Trainor P, Carlisle S, Tsai MY, Criqui MH, DeFilippis A, et al. Aspirin and cardiovascular risk in individuals with elevated Lipoprotein(a): the Multi-Ethnic study of atherosclerosis. J Am Heart Assoc. 2024;13(3):e033562.","journal-title":"J Am Heart Assoc"},{"key":"2255_CR75","doi-asserted-by":"crossref","unstructured":"Razavi AC, Richardson LTC, Coronado F, Dzaye O, Bhatia HS, Mehta A et al. Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a). Am J Prev Cardiol. 2024;18(March):100674.","DOI":"10.1016\/j.ajpc.2024.100674"},{"issue":"19","key":"2255_CR76","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-Term use of Ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791\u2013800.","journal-title":"N Engl J Med"},{"issue":"9","key":"2255_CR77","first-page":"2","volume":"2","author":"SM Patel","year":"2023","unstructured":"Patel SM, Bonaca MP, Morrow DA, Palazzolo MG, Jarolim P, Steg PG, et al. Lipoprotein(a) and benefit of antiplatelet therapy: insights from the PEGASUS-TIMI 54 trial. JACC: Adv. 2023;2(9):2\u20134.","journal-title":"JACC: Adv"},{"issue":"9","key":"2255_CR78","doi-asserted-by":"publisher","first-page":"e023578","DOI":"10.1161\/JAHA.121.023578","volume":"11","author":"K Cui","year":"2022","unstructured":"Cui K, Yin D, Zhu C, Song W, Wang H, Jia L, et al. How do Lipoprotein(a) concentrations affect clinical outcomes for patients with stable coronary artery disease who underwent different dual antiplatelet therapy after percutaneous coronary intervention?? J Am Heart Assoc. 2022;11(9):e023578.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2255_CR79","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u201355.","journal-title":"N Engl J Med"},{"key":"2255_CR80","doi-asserted-by":"crossref","unstructured":"Cho L, Nicholls SJ, Nordestgaard BG, Landmesser U, Tsimikas S, Blaha MJ, Leitersdorf E, et al. Design and rationale of Lp (a) HORIZON trial: assessing the effect of Lipoprotein (a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp (a). Am Heart J., 2025;287:1\u20139. https:\/\/classic.clinicaltrials.gov\/ct2","DOI":"10.1016\/j.ahj.2025.03.019"},{"issue":"20","key":"2255_CR81","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, L\u00f3pez JAG, Lepor NE, Baum SJ, et al. Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387(20):1855\u201364.","journal-title":"N Engl J Med"},{"issue":"12","key":"2255_CR82","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/eurheartj\/ehae781","volume":"46","author":"G Kaur","year":"2025","unstructured":"Kaur G, Rosenson RS, Gencer B, L\u00f3pez JAG, Lepor NE, Baum SJ, et al. Olpasiran Lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study. Eur Heart J. 2025;46(12):1162\u20134.","journal-title":"Eur Heart J"},{"issue":"11","key":"2255_CR83","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","volume":"79","author":"C Yeang","year":"2022","unstructured":"Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, et al. Effect of Pelacarsen on lipoprotein(a) cholesterol and corrected Low-Density lipoprotein cholesterol. J Am Coll Cardiol. 2022;79(11):1035\u201346.","journal-title":"J Am Coll Cardiol"},{"key":"2255_CR84","doi-asserted-by":"publisher","unstructured":"Rosenson RS, L\u00f3pez JAG, Gaudet D, Baum SJ, Stout E, Lepor NE et al. Olpasiran, oxidized phospholipids, and systemic inflammatory biomarkers. JAMA Cardiol. 2025. https:\/\/doi.org\/10.1001\/jamacardio.2024.5433.","DOI":"10.1001\/jamacardio.2024.5433"},{"issue":"21","key":"2255_CR85","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an Extended-Duration short interfering RNA targeting Lipoprotein(a). JAMA. 2023;330(21):2075.","journal-title":"JAMA"},{"issue":"23","key":"2255_CR86","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","volume":"332","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran\u2014A Small-Interfering RNA targeting Lipoprotein(a). JAMA. 2024;332(23):1992.","journal-title":"JAMA"},{"issue":"11","key":"2255_CR87","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jama.2023.16503","volume":"330","author":"SJ Nicholls","year":"2023","unstructured":"Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, et al. Muvalaplin, an oral small molecule inhibitor of Lipoprotein(a) formation. JAMA. 2023;330(11):1042.","journal-title":"JAMA"},{"issue":"3","key":"2255_CR88","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","volume":"333","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, et al. Oral Muvalaplin for Lowering of Lipoprotein(a). JAMA. 2025;333(3):222.","journal-title":"JAMA"},{"key":"2255_CR89","doi-asserted-by":"crossref","unstructured":"Ballantyne CM, Ditmarsch M, Kastelein JJ, Nelson AJ, Kling D, Hsieh A et al. Obicetrapib plus Ezetimibe as an adjunct to high-intensity Statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023;17(4):491\u2013503.","DOI":"10.1016\/j.jacl.2023.05.098"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02255-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02255-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02255-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:06:14Z","timestamp":1772096774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02255-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2255"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02255-2","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"17 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"104"}}